DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia

Information source: New York University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Tachycardia, Ventricular

Intervention: Remifentanil (Drug)

Phase: N/A

Status: Completed

Sponsored by: New York University School of Medicine

Official(s) and/or principal investigator(s):
Misha Kogan, MD, Principal Investigator, Affiliation: NYU School of Medicine

Summary

Determine effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent premature ventricular contractions (PVCs) of non-ischemic origin

Clinical Details

Official title: Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Inhibition of Idiopathic Ventricular Tachycardia

PVC Suppression With Remifentanil Sedation

Detailed description: The purpose of the study is to determine the effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin. Remifentanil is an analgesic- synthetic opiate with an very short half life. It is rapidly broken down by enzymes in the blood and is ideally suited for continuous sedation. The effect is practically eliminated within 5 minutes after the intravenous sedation is stopped. You are being asked to participate in this study because you are already scheduled to undergo EP studies under the care of your cardiologist for the ablation of idiopathic ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients scheduled to undergo EP studies for the ablation of idiopathic ventricular

tachycardia and/or persistent frequent PVCs of non-ischemic origin

- Patients between 18 and 65

- ASA 1-3

Exclusion Criteria:

- ASA 4 and 5

- Age 18 and 65

Locations and Contacts

NYU Langone Medical Center, New York, New York 10016, United States
Additional Information

Related publications:

Garofalo NA, Teixeira-Neto FJ, Schwartz DS, Vailati Mdo C, Steagall PV. Effects of the opioid remifentanil on the arrhythmogenicity of epinephrine in halothane-anesthetized dogs. Can J Vet Res. 2008 Jul;72(4):362-6.

Starting date: July 2011
Last updated: May 9, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017